Why a $3.5 Million Bet Targets Avantor Amid a 54% Stock Drop

Circumference Group established a new 305,000-share position in Avantor (AVTR) valued at $3.5M as of Dec. 31, 2025, representing 3.77% of its 13F-reportable assets. Avantor trades at $7.51, down ~54% Y/Y, with market cap ~$5.1B, TTM revenue ~$6.55B and a TTM net loss of $530.2M; adjusted EBITDA exceeded $1B and free cash flow approached $500M. Management’s “Revival” program targets go-to-market and supply-chain fixes to recover margins, but one-time charges and recent underperformance vs. the S&P 500 weigh on near-term outlook. The 13F purchase is a notable positioning move but is unlikely to drive material market reaction by itself.

Analysis

Avantor sits at the intersection of defensive consumables demand and cyclical industrial exposure; its core value is in stable replacement-driven volumes, not blockbuster R&D wins. If management can extract ~200–300bps of gross margin through supply-chain and go-to-market fixes, free cash flow should re-rate materially because working capital tailwinds compound operating improvements over 2–4 quarters.

Second-order winners from a successful turnaround are contract manufacturers and mid-tier CROs that source bundled procurement services; suppliers with concentrated exposure to Avantor could face price pressure, and private regional distributors may see accelerated share loss as buying consolidates. Conversely, a failure to execute on execution/cost programs risks turning one-time charges into recurring earnings drift, with the first signal being sequential EBITDA conversion and inventory days moving in the wrong direction over a single quarter.

Near-term catalysts to watch are quarterly FCF print and concrete, quantifiable milestones within the cost program (e.g., SG&A savings run-rate and logistics SKU rationalization), both tradable within 1–3 quarters. The contrarian view: the market likely over-penalizes cyclicality while underweighting cash generation optionality — but that optionality is binary and hinges on execution, so position sizing and event-based hedges are essential for asymmetric upside over a 12–24 month horizon.

Key Decisions for Investors

• Long AVTR (12–18 month horizon): Buy a 0.5–1.0% NAV position in stock or 9–12 month call LEAPS (out-of-the-money $10-ish strike depending on current price) paired with a 20–25% downside put as protection; target 40–80% upside if gross margins recover 200–300bps and FCF conversion sustains, downside limited to ~50–60% if execution fails.
• Pair trade (12 months): Long AVTR / Short TMO sized to neutralize biotech sector beta (e.g., dollar-neutral 0.5% NAV each). Rationale: captures idiosyncratic margin-recovery upside at Avantor while hedging industry demand moves; unwind once gross margin divergence exceeds 200bps or on clear program delivery.
• Event trade (0–3 months): Small tactical long into next quarter if FCF or adjusted EBITDA shows sequential improvement; size as 0.25% NAV and use a tight 15–20% stop-loss. If metrics disappoint, flip to quick exit—this is an execution binary where rapid de-risking preserves capital.
• Risk-management rule: Treat Avantor as a binary turnaround—cap any single exposure to 1% NAV without hedges and require two consecutive quarters of improving operating metrics (margin, inventory days, FCF) before adding to core position.